Background and Objectives: There is little information on changes in the process and outcomes of intensive tobacco dependence treatment during the COVID-19 pandemic. The following characteristics were evaluated: interest in treatment, the number of face-to-face or telephone follow-ups, the duration of pharmacotherapy use, and the success rate. The aim of our study was to compare the number of patients who entered tobacco dependence treatment programmes and evaluate the one-year success rate in patients three years before and three years after the COVID-19 pandemic. Materials and Methods: A single-site retrospective cohort study using data from patients treated at the Centre for Tobacco Dependence in Prague, Czech Republic, between 2017 and 2022 (n = 2039) was performed. The one-year abstinence rate was validated by measuring carbon monoxide in exhaled air (6 ppm cut-off). Patients were divided into two groups: the group for which treatment was initiated in 2017-2019 (i.e., before the COVID-19 pandemic, BC; n= 1221) and the group for which treatment was initiated in 2020-2022 (i.e., during the COVID-19 pandemic, DC; n = 818). Results: No significant differences in the success rate of tobacco dependence treatment were found between the two groups (BC group, 40.5% (494/1221) vs. DC group, 42.2% (345/818)) (χ2 (1, N = 2.039) = 0.6, p = 0.440). Furthermore, differences were not found in sex, education level, age at first cigarette, the duration of pharmacotherapy use, or the number of in-person visits. In contrast, there was an increase in the number of telephone contacts between the groups (18.7% (SD = 17.5%) vs. 32.9% (SD = 18.2%), p < 0.001). Conclusions: The number of patients who started treatment during the COVID-19 pandemic decreased by one-third compared to that during the 3-year period before the pandemic. The overall treatment success rate did not change significantly even with the increase in the number of telephone visits with the therapist.

Centre for Tobacco Dependent of the 3rd Medical Department Department of Endocrinology and Metabolism 1st Faculty of Medicine Charles University Prague and General University Hospital 12808 Prague Czech Republic

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague 27201 Kladno Czech Republic

Institute of Hygiene and Epidemiology 1st Faculty of Medicine Charles University Prague and General University Hospital 12808 Prague Czech Republic

Zobrazit více v PubMed

2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating Tobacco Use and Dependence: 2008 Update U.S. Public Health Service Clinical Practice Guideline Executive Summary. Respir. Care. 2008;53:1217–1222. PubMed

Ofori S., Lu C., Olasupo O.O., Dennis B.B., Fairbairn N., Devereaux P.J., Mbuagbaw L. Cytisine for Smoking Cessation: A Systematic Review and Meta-Analysis. Drug Alcohol Depend. 2023;251:110936. doi: 10.1016/j.drugalcdep.2023.110936. PubMed DOI

Králíková E., Češka R., Pánková A., Štěpánková L., Zvolská K., Felbrová V., Kulovaná S., Zvolský M. Doporučení pro Léčbu Závislosti Na Tabáku. Vnitř. Lékařství. 2015;61((Suppl. 1)):3–15. PubMed

Policy Recommendations for Smoking Cessation and Treatment of Tobacco Dependence: Tools for Public Health. [(accessed on 17 May 2024)]. Available online: https://www.who.int/publications-detail-redirect/policy-recommendations-for-smoking-cessation-and-treatment-of-tobacco-dependence-tools-for-public-health.

Bommele J., Hopman P., Walters B.H., Geboers C., Croes E., Fong G.T., Quah A.C.K., Willemsen M. The Double-Edged Relationship between COVID-19 Stress and Smoking: Implications for Smoking Cessation. Tob. Induc. Dis. 2020;18:63. doi: 10.18332/tid/125580. PubMed DOI PMC

Di Renzo L., Gualtieri P., Pivari F., Soldati L., Attinà A., Cinelli G., Leggeri C., Caparello G., Barrea L., Scerbo F., et al. Eating Habits and Lifestyle Changes during COVID-19 Lockdown: An Italian Survey. J. Transl. Med. 2020;18:229. doi: 10.1186/s12967-020-02399-5. PubMed DOI PMC

Klemperer E.M., West J.C., Peasley-Miklus C., Villanti A.C. Change in Tobacco and Electronic Cigarette Use and Motivation to Quit in Response to COVID-19. Nicotine Tob. Res. 2020;22:1662–1663. doi: 10.1093/ntr/ntaa072. PubMed DOI PMC

Koopmann A., Georgiadou E., Reinhard I., Müller A., Lemenager T., Kiefer F., Hillemacher T. The Effects of the Lockdown during the COVID-19 Pandemic on Alcohol and Tobacco Consumption Behavior in Germany. Eur. Addict. Res. 2021;27:242–256. doi: 10.1159/000515438. PubMed DOI PMC

Sidor A., Rzymski P. Dietary Choices and Habits during COVID-19 Lockdown: Experience from Poland. Nutrients. 2020;12:1657. doi: 10.3390/nu12061657. PubMed DOI PMC

Rantis K., Panagiotidis P., Parlapani E., Holeva V., Tsapakis E., Diakogiannis I. Substance Use during the COVID-19 Pandemic in Greece. J. Subst. Use. 2021;27:231–238. doi: 10.1080/14659891.2021.1941344. DOI

Mellos E., Paparrigopoulos T. Substance Use during the COVID-19 Pandemic: What Is Really Happening? Psychiatr. Psychiatr. 2022;33:17–20. doi: 10.22365/jpsych.2022.072. PubMed DOI

Chen D.T. The psychosocial impact of the COVID-19 pandemic on changes in smoking behavior: Evidence from a nationwide survey in the UK. Tob. Prev. Cessat. 2020;6:59. doi: 10.18332/tpc/126976. PubMed DOI PMC

Csémy L., Dvořáková Z., Fialová A., Kodl M., Malý M., Skývová M. Národní Výzkum Užívání Tabáku a Alkoholu v České Republice 2021 (NAUTA). Státní Zdravotní Ústav, Praha. 2022. [(accessed on 15 August 2024)]. Available online: https://archiv.szu.cz/uploads/documents/szu/aktual/NAUTA_2021.pdf.

Samuels E.A., Clark S.A., Wunsch C., Jordison Keeler L.A., Reddy N., Vanjani R., Wightman R.S. Innovation during COVID-19: Improving Addiction Treatment Access. J. Addict. Med. 2020;14:e8–e9. doi: 10.1097/ADM.0000000000000685. PubMed DOI PMC

Ornell F., Moura H.F., Scherer J.N., Pechansky F., Kessler F.H.P., von Diemen L. The COVID-19 Pandemic and Its Impact on Substance Use: Implications for Prevention and Treatment. Psychiatry Res. 2020;289:113096. doi: 10.1016/j.psychres.2020.113096. PubMed DOI PMC

Harker N., Johnson K., Erasmus J., Myers B. COVID 19-Impact on Substance Use Treatment Utilization and Provision in South Africa. Subst. Abuse Treat. Prev. Policy. 2022;17:15. doi: 10.1186/s13011-022-00446-6. PubMed DOI PMC

Jackson S.E., Garnett C., Shahab L., Oldham M., Brown J. Association of the COVID-19 Lockdown with Smoking, Drinking and Attempts to Quit in England: An Analysis of 2019–20 Data. Addiction. 2021;116:1233–1244. doi: 10.1111/add.15295. PubMed DOI PMC

Meacham M.C., Vogel E.A., Thrul J., Ramo D.E., Satre D.D. Addressing Cigarette Smoking Cessation Treatment Challenges during the COVID-19 Pandemic with Social Media. J. Subst. Abuse Treat. 2021;129:108379. doi: 10.1016/j.jsat.2021.108379. PubMed DOI PMC

Jorge A., Rodriguez M.D., Joseph R., Betancourt M.D., Thomas D., Sequist M.D., Ishani Ganguli M.D. Differences in the Use of Telephone and Video Telemedicine Visits during the COVID-19 Pandemic. Am. J. Manag. Care. 2021;27:21. PubMed PMC

Baum A., Kaboli P.J., Schwartz M.D. Reduced In-Person and Increased Telehealth Outpatient Visits during the COVID-19 Pandemic. Ann. Intern. Med. 2021;174:129–131. doi: 10.7326/M20-3026. PubMed DOI PMC

Mark T.L., Treiman K., Padwa H., Henretty K., Tzeng J., Gilbert M. Addiction Treatment and Telehealth: Review of Efficacy and Provider Insights during the COVID-19 Pandemic. Psychiatr. Serv. 2022;73:484–491. doi: 10.1176/appi.ps.202100088. PubMed DOI

Jackson S.E., Cox S., Shahab L., Brown J. Prevalence of Use and Real-World Effectiveness of Smoking Cessation Aids during the COVID-19 Pandemic: A Representative Study of Smokers in England. Addiction. 2022;117:2504–2514. doi: 10.1111/add.15903. PubMed DOI PMC

Kayhan Tetik B., Gedik Tekinemre I., Taş S. The Effect of the COVID-19 Pandemic on Smoking Cessation Success. J. Community Health. 2021;46:471–475. doi: 10.1007/s10900-020-00880-2. PubMed DOI PMC

Veldhuizen S., Selby P., Wong B., Zawertailo L. Effect of COVID-19 on Smoking Cessation Outcomes in a Large Primary Care Treatment Programme: An Observational Study. BMJ Open. 2021;11:e053075. doi: 10.1136/bmjopen-2021-053075. PubMed DOI PMC

Turan P.A., Turan O. Impacts of the Covid-19 Pandemic on Smoking Cessation Success. Afr. Health Sci. 2023;23:431–436. doi: 10.4314/ahs.v23i3.50. PubMed DOI PMC

Blithikioti C., Nuño L., Paniello B., Gual A., Miquel L. Impact of COVID-19 Lockdown on Individuals under Treatment for Substance Use Disorders: Risk Factors for Adverse Mental Health Outcomes. J. Psychiatr. Res. 2021;139:47–53. doi: 10.1016/j.jpsychires.2021.05.006. PubMed DOI PMC

West R., Hajek P., Stead L., Stapleton J. Outcome Criteria in Smoking Cessation Trials: Proposal for a Common Standard. Addiction. 2005;100:299–303. doi: 10.1111/j.1360-0443.2004.00995.x. PubMed DOI

Králíková E., Zvolská K., Štěpánková L., Pánková A. Tobacco Dependence Treatment Guidelines. Cas. Lek. Cesk. 2022;161:33–43. PubMed

Nides M., Rigotti N.A., Benowitz N., Clarke A., Jacobs C. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial) Nicotine Tob. Res. 2021;23:1656–1663. doi: 10.1093/ntr/ntab073. PubMed DOI PMC

Stepankova L., Kralikova E., Zvolska K., Pankova A., Adamcekova Z., Kuhn M., Noland D. Comparison between Success Rates for Smokers Re-Treated by a Smokers’ Clinic and Success Rates for Smokers Treated for the First Time. Addiction. 2021;116:346–355. doi: 10.1111/add.15175. PubMed DOI

Hajkova D., Sandora J., Žídková R., Malinakova K., Novak L. Effects of the COVID-19 pandemic on Czech citizens: How do depression and anxiety symptoms influence cognitive, behavioral, and emotional changes? Front. Psychol. 2023;14:1204824. doi: 10.3389/fpsyg.2023.1204824. PubMed DOI PMC

Bäuerle A., Teufel M., Musche V., Weismüller B., Kohler H., Hetkamp M., Dörrie N., Schweda A., Skoda E.M. Increased generalized anxiety, depression and distress during the COVID-19 pandemic: A cross-sectional study in Germany. J. Public Health. 2020;42:672–678. doi: 10.1093/pubmed/fdaa106. PubMed DOI PMC

Mamun M.A., Sakib N., Gozal D., Bhuiyan A.I., Hossain S., Bodrud-Doza M., Al Mamun F., Hosen I., Safiq M.B., Abdullah A.H., et al. The COVID-19 pandemic and serious psychological consequences in Bangladesh: A population-based nationwide study. J. Affect. Disord. 2021;279:462–472. doi: 10.1016/j.jad.2020.10.036. PubMed DOI PMC

Midorikawa H., Aiba M., Lebowitz A., Taguchi T., Shiratori Y., Ogawa T., Takahashi A., Takahashi S., Nemoto K., Arai T., et al. Confirming validity of the Fear of COVID-19 Scale in Japanese with a nationwide large-scale sample. PLoS ONE. 2021;16:e0246840. doi: 10.1371/journal.pone.0246840. PubMed DOI PMC

Remr J. Psychometric Performance of the Fear of COVID-19 Scale (FCV-19S) and Its Validation in Czechia. Sustainability. 2023;15:8990. doi: 10.3390/su15118990. DOI

Stănculescu E. Fear of COVID-19 in Romania: Validation of the Romanian Version of the Fear of COVID-19 Scale Using Graded Response Model Analysis. Int. J. Ment. Health Addict. 2022;20:1094–1109. doi: 10.1007/s11469-020-00428-4. PubMed DOI PMC

Broche-Pérez Y., Fernández-Fleites Z., Jiménez-Puig E., Fernández-Castillo E., Rodríguez-Martin B.C. Gender and Fear of COVID-19 in a Cuban Population Sample. Int. J. Ment. Health Addict. 2022;20:83–91. doi: 10.1007/s11469-020-00343-8. PubMed DOI PMC

Nomura A., Tanigawa T., Muto T., Oga T., Fukushima Y., Kiyosue A., Miyazaki M., Hida E., Satake K. Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority Trial. J. Med. Internet Res. 2019;21:e13520. doi: 10.2196/13520. PubMed DOI PMC

Richter K.P., Shireman T.I., Ellerbeck E.F., Cupertino A.P., Catley D., Cox L.S., Preacher K.J., Spaulding R., Mussulman L.M., Nazir N., et al. Comparative and Cost Effectiveness of Telemedicine versus Telephone Counseling for Smoking Cessation. J. Med. Internet Res. 2015;17:e113. doi: 10.2196/jmir.3975. PubMed DOI PMC

Minian N., Veldhuizen S., Tanzini E., Duench S., deRuiter W.K., Barker M., Zawertailo L., Melamed O.C., Selby P. Changes in the Reach of a Smoking Cessation Program in Ontario, Canada, during the COVID-19 Pandemic: A Cross-Sectional Study. CMAJ Open. 2021;9:E957–E965. doi: 10.9778/cmajo.20210053. PubMed DOI PMC

Veldhuizen S., Mahinpey N., Zawertailo L., Minian N., Melamed O., Selby P. Effects of COVID-19-Related Disruptions on Service Use in a Large Smoking Cessation Program. Nicotine Tob. Res. 2022;24:1567–1572. doi: 10.1093/ntr/ntac103. PubMed DOI PMC

Bandi P., Asare S., Majmundar A., Xue Z., Han X., Westmaas J.L., Nargis N., Jemal A. Changes in Smoking Cessation-Related Behaviors among US Adults during the COVID-19 Pandemic. JAMA Netw. Open. 2022;5:e2225149. doi: 10.1001/jamanetworkopen.2022.25149. PubMed DOI PMC

Melamed O.C., deRuiter W.K., Buckley L., Selby P. Coronavirus Disease 2019 and the Impact on Substance Use Disorder Treatments. Psychiatr. Clin. N. Am. 2022;45:95–107. doi: 10.1016/j.psc.2021.11.006. PubMed DOI PMC

Zvolská K., Zvolský M., Čady J., Králíková E. Intenzivní léčba závislosti na tabáku v Česku v letech 2010–2022. Časopis Lékařů Českých. 2024;163:44–48.